IMVT Share Price Performance
US$18.94
-11.01 (-36.76%)
Price US$18.94
Share PriceUS$18.94
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jul 22
Immunovant, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
IMVT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Immunovant, Inc. Key Details
About IMVT
- Founded
- 2018
- Employees
- 362
- CEO
- WebsiteView website
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
